Moderna cuts 2024 sales forecast, sees low EU vaccine revenue into 2026
MODERNA on Thursday (Aug 1) cut its 2024 sales forecast for Covid-19 and respiratory syncytial virus vaccines by up to ...
MODERNA on Thursday (Aug 1) cut its 2024 sales forecast for Covid-19 and respiratory syncytial virus vaccines by up to ...
The US government has awarded US$176 million to Moderna to advance development of its bird flu vaccine, the company said ...
Sanofi and Novavax signed a licensing agreement that includes commercialising a combined Covid-19 and flu shot. Novavax will receive US$500 million ...
ASTRAZENECA said on Tuesday (May 7) it had initiated the worldwide withdrawal of its Covid-19 vaccine due to a “surplus ...
PFIZER lifted its annual profit forecast on Wednesday (May 1), banking on cost cuts and better-than-expected demand for its Covid ...
AstraZeneca has admitted in court for the first time that its Covid vaccine can lead to a severe blood clotting ...
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday (Apr 25), accusing them of infringing GSK patents related ...
Moderna on Friday announced in a press release it was suing Pfizer and BioNTech for patent infringement over intellectual property ...
When the initial COVID-19 vaccine rollout happened in the United States, finding a leftover dose seemed to be the “golden ...
Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.
© 2025 Forbes 40under40. All Rights Reserved.